Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication

Expert Opinion on Drug Safety

Volumn 10, Issue 4, 2011, Pages 521-528

  Raisch, Dennis W ^a   Campbell, Wesley ^a   Garg, Vishvas ^a   Qureshi, Zaina P ^b   Bookstaver, P Brandon ^b   Norris, Leann B ^b   Bennett, Charles L ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

anaphylactic reaction; docetaxel; mortality; paclitaxel

Indexed keywords

ANTIHISTAMINIC AGENT; CARBOPLATIN; CIMETIDINE; CISPLATIN; CLEMASTINE; CLEMASTINE FUMARATE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DEXCHLORPHENIRAMINE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FAMOTIDINE; FLUOROURACIL; GEMCITABINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; METHYLPREDNISOLONE; PACLITAXEL; RANITIDINE; STEROID; TRASTUZUMAB;

ANAPHYLAXIS; ARTICLE; BRONCHOSPASM; CASE REPORT; DATA EXTRACTION; DISEASE ASSOCIATION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DYSPNEA; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; HYPOTENSION; LUNG EDEMA; MEDLINE; MORTALITY; PROPHYLACTIC PREMEDICATION; PROPHYLAXIS; SHOCK; UNCONSCIOUSNESS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANAPHYLAXIS; COHORT STUDIES; DRUG LABELING; DRUG TOXICITY; HUMANS; PACLITAXEL; PREMEDICATION; TAXOIDS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79958809393     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.582865     Document Type: Article

References (40)

1. Crown J, OLeary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 2004;9(Suppl 2):24-32 (Pubitemid 38747840)
2. Marupudi NI, Han JE, Li KW, et al. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 2007;6(5):609-21 (Pubitemid 351308218)
3. Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994;48(5):794-847 (Pubitemid 24304427)
4. Moon C, Verschraegen CF, Bevers M, et al. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anticancer Drugs 2000;11(7):565-8
5. Zanotti KM, Markman M. Prevention and management of antineoplastic- induced hypersensitivity reactions. Drug Saf 2001;24(10):767-79 (Pubitemid 32848355)
6. Taxotere Prescribing Information. Sanofi-Aventis US LLC. Bridgewater, NJ; 2010
7. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37(13):1590-8 (Pubitemid 32778603)
8. Szebeni J, Alving CR, Savay S, et al. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol 2001;1(4):721-35 (Pubitemid 32206533)
9. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998;90(4):300-6 (Pubitemid 28182386)
10. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8(7):1263-8 (Pubitemid 20195638)
11. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003;24(3):253-62 (Pubitemid 36584220)
12. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003:42:7:665-85 (Pubitemid 36936530)
13. Engels FK, Mathot RA, Verweij J. Alternative drug formulations of docetaxel: a review. Anticancer Drugs 2007;18(2):95-103 (Pubitemid 44967420)
14. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001;10(6):483-6 (Pubitemid 34100774)
15. Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf 2003;26(3):159-86 (Pubitemid 36308102)
16. Denman JP, Gilbar PJ, Abdi EA. Hypersensitivity reaction (HSR) to docetaxel after a previous HSR to paclitaxel. J Clin Oncol 2002;20(11):2760-1 (Pubitemid 34575656)
17. Fader AN, Rose PG. Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. Int J Gynecol Cancer 2009;19(7):1281-3
18. Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 2004;90(2):304-5 (Pubitemid 38250619)
19. Lehoczky O, Bagameri A, Udvary J, Pulay T. Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients. J Obstet Gynaecol 2002;22(3):312-13 (Pubitemid 34628160)
20. Micha JP, Goldstein BH, Birk CL, et al. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol 2006;100(2):437-8 (Pubitemid 43075284)
21. Prieto Garcia A, Pineda de la Losa F. Immunoglobulin E-mediated severe anaphylaxis to paclitaxel. J Investig Allergol Clin Immunol 2010;20(2):170-1
22. Priore GD, Smith P, Warshal DP, et al. Paclitaxel-Associated hypersensitivity reaction despite high-dose steriods and prolonged infusions. Gynecol Oncol 1995;56(2):316-18
23. van Herpen CM, van Hoesel QG, Punt CJ. Paclitaxel-induced severe hypersensitivity reaction occurring as a late toxicity. Ann Oncol 1995;6(8):852
24. Hauben M. A brief primer on automated signal detection. Ann Pharmacother 2003;37(7-8):1117-23 (Pubitemid 36875247)
25. Ardavanis A, Tryfonopoulos D, Yiotis I, et al. Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs 2004;15(6):581-5 (Pubitemid 38932325)
26. Dizon DS, Schwartz J, Rojan A, et al. Cross-sensitivity between paclitaxel and docetaxel in a womens cancers program. Gynecol Oncol 2006;100(1):149-51 (Pubitemid 41815065)
27. Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122(3):574-80
28. Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 2005;96(3):824-9 (Pubitemid 40255508)
29. Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005;99(2):393-9 (Pubitemid 41502850)
30. Bennett CL, Adegroro OS, Calhoun E, Raisch DW. Beyond the black box: drugand device-associated hypersensitivity events. Drug Healthc Patient Saf 2010;2:1-5
31. Kwon JS, Elit L, Finn M, et al. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol 2002;84(3):420-5 (Pubitemid 34211869)
32. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf 2009;32(1):19-31
33. Hsia CC, Zurawska JH, Tong MZ, et al. Recombinant activated factor VII in the treatment of non-haemophilia patients: physician under-reporting of thromboembolic adverse events. Transfus Med 2009;19(1):43-9
34. Irujo M, Beitia G, Bes-Rastrollo M, et al. Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region. Drug Saf 2007;30(11):1073-82 (Pubitemid 350036605)
35. Aziz Z, Siang TC, Badarudin NS. Reporting of adverse drug reactions: predictors of under-reporting in Malaysia. Pharmacoepidemiol Drug Saf 2007;16(2):223-8
36. Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review. Drug Saf 2006;29(5):385-96
37. Mittmann N, Knowles SR, Gomez M, et al. Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis. Drug Saf 2004;27(7):477-87 (Pubitemid 38736875)
38. Backstrom M, Mjorndal T, Dahlqvist R. Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf 2004;13(7):483-7 (Pubitemid 38996859)
39. van der Heijden PG, van Puijenbroek EP, van Buuren S, van der Hofstede JW. On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Stat Med 2002;21(14):2027-44 (Pubitemid 34752621)
40. Irizarry L, Luu T, McKoy J, et al. Cremophor EL-containing paclitaxel induced anaphylaxis: a call to action. Community Oncol 2009;8(3):133-4